Steven Kridel to Enzyme Inhibitors
This is a "connection" page, showing publications Steven Kridel has written about Enzyme Inhibitors.
Connection Strength
0.680
-
Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 2007 Feb 01; 67(3):1262-9.
Score: 0.270
-
Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004 Mar 15; 64(6):2070-5.
Score: 0.221
-
Little JL, Kridel SJ. Fatty acid synthase activity in tumor cells. Subcell Biochem. 2008; 49:169-94.
Score: 0.072
-
Pemble CW, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007 Aug; 14(8):704-9.
Score: 0.069
-
Hill TK, Davis AL, Wheeler FB, Kelkar SS, Freund EC, Lowther WT, Kridel SJ, Mohs AM. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines. Mol Pharm. 2016 Mar 07; 13(3):720-8.
Score: 0.032
-
Zhao W, Kridel S, Thorburn A, Kooshki M, Little J, Hebbar S, Robbins M. Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer. 2006 Oct 09; 95(7):869-78.
Score: 0.016